Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Lipinski

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Pharmaceutical Sciences|November 16, 2002
Single-mode compound retrieval for QSAR, QSPR data sets, and batch mode exact structure searchingChristopher A Lipinski
Current Opinion in Chemical Biology|July 11, 2006
The anti-intellectual effects of intellectual propertyChristopher A Lipinski
Drug Discovery Today. Technologies|July 2, 2014
Lead- and drug-like compounds: the rule-of-five revolutionChristopher A Lipinski
Drug Discovery Today|January 28, 2003
Chris Lipinski discusses life and chemistry after the Rule of FiveChristopher A Lipinski
Advanced Drug Delivery Reviews|May 8, 2016
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisionsChristopher A Lipinski
Annual Reports in Computational Chemistry|April 15, 2020
Capter 11 Filtering in Drug DiscoveryChristopher A Lipinski
Expert Opinion on Therapeutic Targets|December 17, 2009
Targeting Pyk2 for therapeutic interventionChristopher A Lipinski, Joseph C Loftus
Frontiers in Pharmacology|August 25, 2022
Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugsChristopher A Lipinski, Andrew G Reaume
Bioorganic & Medicinal Chemistry|March 24, 2020
High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of conceptChristopher A Lipinski, Andrew G Reaume
International Journal for Parasitology. Drugs and Drug Resistance|June 18, 2017
The rule of five should not impede anti-parasitic drug developmentJames H McKerrow, Christopher A Lipinski
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Pharmaceutical Sciences|November 16, 2002
Single-mode compound retrieval for QSAR, QSPR data sets, and batch mode exact structure searchingChristopher A Lipinski
Current Opinion in Chemical Biology|July 11, 2006
The anti-intellectual effects of intellectual propertyChristopher A Lipinski
Drug Discovery Today. Technologies|July 2, 2014
Lead- and drug-like compounds: the rule-of-five revolutionChristopher A Lipinski
Drug Discovery Today|January 28, 2003
Chris Lipinski discusses life and chemistry after the Rule of FiveChristopher A Lipinski
Advanced Drug Delivery Reviews|May 8, 2016
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisionsChristopher A Lipinski
Annual Reports in Computational Chemistry|April 15, 2020
Capter 11 Filtering in Drug DiscoveryChristopher A Lipinski
Expert Opinion on Therapeutic Targets|December 17, 2009
Targeting Pyk2 for therapeutic interventionChristopher A Lipinski, Joseph C Loftus
Frontiers in Pharmacology|August 25, 2022
Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugsChristopher A Lipinski, Andrew G Reaume
Bioorganic & Medicinal Chemistry|March 24, 2020
High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of conceptChristopher A Lipinski, Andrew G Reaume
International Journal for Parasitology. Drugs and Drug Resistance|June 18, 2017
The rule of five should not impede anti-parasitic drug developmentJames H McKerrow, Christopher A Lipinski
Pageof 4